Chronic myeloid leukemia (CML) is distinguished by the presence of the BCR-ABL hybrid oncogene and expression of Bcr-Abl oncoprotein, which mediates the activation of signaling pathways leading to leukemogenesis [1]. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.